Kaken Pharmaceutical Co (TSE:4521) Interest Expense : 円-18 Mil (TTM As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kaken Pharmaceutical Co's interest expense for the three months ended in Dec. 2023 was 円 -5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was 円-18 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kaken Pharmaceutical Co's Operating Income for the three months ended in Dec. 2023 was 円 3,361 Mil. Kaken Pharmaceutical Co's Interest Expense for the three months ended in Dec. 2023 was 円 -5 Mil. Kaken Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 was 672.20. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kaken Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Kaken Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Interest Expense Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-17.00

Kaken Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-4.00	-5.00	-4.00	-4.00	-5.00

Kaken Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-18 Mil.

Kaken Pharmaceutical Co (TSE:4521) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kaken Pharmaceutical Co's Interest Expense for the three months ended in Dec. 2023 was 円-5 Mil. Its Operating Income for the three months ended in Dec. 2023 was 円3,361 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was 円0 Mil.

Kaken Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	3361	/	-5
	=	672.20

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Kaken Pharmaceutical Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines